Personal information

No personal information available

Activities

Collapse all

Employment (1)

Hoffmann-La-Roche: Basel, Basel Stadt, CH

2001-01-01 to present | Statistician (Biostatistics)
Employment
Source: Self-asserted source
Ulrich Beyer

Professional activities (1)

International Biometric Society: Washington, DC, US

1997 to present
Membership
Source: Self-asserted source
Ulrich Beyer

Works (48)

Dose Optimization for Novel Oncology Agents: Design Options and Strategies

Statistics in Biopharmaceutical Research
2024-07-02 | Journal article
DOI: 10.1080/19466315.2024.2308856
Part of ISSN: 1946-6315
Contributors: David Dejardin; Bo Huang; Ying Yuan; Ulrich Beyer; Jane Fridlyand; Jiawen Zhu
Source: Self-asserted source
Ulrich Beyer

A Composite Decision Rule of CD8+ T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

Clinical Cancer Research
2024-02-16 | Journal article
DOI: 10.1158/1078-0432.CCR-23-1572
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Data from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.c.7077820.v1
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Data from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.c.7077820
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Data 1 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232536
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Data 1 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232536.v1
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S1 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232533
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S1 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232533.v1
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S2 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232530
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S2 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232530.v1
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S3 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232527.v1
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S3 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232527
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S4 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232524.v1
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S4 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232524
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S5 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232521.v1
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S5 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232521
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S6 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232518
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Figure S6 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232518.v1
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Table S1 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232512.v1
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Supplementary Table S1 from A Composite Decision Rule of CD8<sup>+</sup> T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials

2024-02-16 | Preprint
DOI: 10.1158/1078-0432.25232512
Contributors: David Dejardin; Anton Kraxner; Annika Blank; Natascha Rieder; Volker Teichgräber; Nicolas Städler; Ulrich Beyer; Bruno Gomes; Jehad Charo
Source: check_circle
Crossref

Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models

British Journal of Cancer
2023 | Journal article
DOI: 10.1038/S41416-023-02190-5
WOSUID: WOS:000935629700005
Contributors: Bruno, Rene; Chanu, Pascal; Kagedal, Matts; Mercier, Francois; Yoshida, Kenta; Guedj, Jeremie; Li, Chunze; Beyer, Ulrich; Jin, Jin Y.
Source: check_circle
Web of Science Researcher Profile Sync

Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel

CPT: Pharmacometrics & Systems Pharmacology
2021 | Journal article
DOI: 10.1002/PSP4.12693
WOSUID: WOS:000680760300001
Contributors: Krishnan, Sreenath M.; Friberg, Lena E.; Bruno, Rene; Beyer, Ulrich; Jin, Jin Y.; Karlsson, Mats O.
Source: check_circle
Web of Science Researcher Profile Sync

Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design

Contemporary Clinical Trials
2021 | Journal article
DOI: 10.1016/J.CCT.2021.106436
WOSUID: WOS:000702860000018
Contributors: Zhu, Jiawen; Bove, Daniel Sabanes; Liao, Ziwei; Beyer, Ulrich; Yung, Godwin; Sarkar, Somnath
Source: check_circle
Web of Science Researcher Profile Sync

A multistate model for early decision‐making in oncology

Biometrical Journal
2019-07-16 | Journal article
DOI: 10.1002/bimj.201800250
Part of ISSN: 0323-3847
Part of ISSN: 1521-4036
Source: Self-asserted source
Ulrich Beyer
grade
Preferred source (of 2)‎

A multistate model for early decision making in oncology

ArXiv
2018 | Journal article
WOSUID: PPRN:15310043
Contributors: Beyer, Ulrich; Dejardin, David; Meller, Matthias; Rufibach, Kaspar; Ulrich Burger, Hans
Source: check_circle
Web of Science Researcher Profile Sync

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

Journal of Clinical Oncology
2018-03-20 | Journal article
DOI: 10.1200/jco.2017.75.1644
Part of ISSN: 0732-183X
Part of ISSN: 1527-7755
Source: Self-asserted source
Ulrich Beyer

Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy

Pharmaceutical Statistics
2017-11 | Journal article
DOI: 10.1002/pst.1818
Part of ISSN: 1539-1604
Source: Self-asserted source
Ulrich Beyer

Roche-Genentech oncology trials – our experience with data sharing via CSDR

European Journal of Cancer
2016-12 | Journal article
DOI: 10.1016/s0959-8049(16)32775-7
Part of ISSN: 0959-8049
Source: Self-asserted source
Ulrich Beyer

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression

JAMA Psychiatry
2016-07-01 | Journal article
DOI: 10.1001/jamapsychiatry.2016.0838
Part of ISSN: 2168-622X
Source: Self-asserted source
Ulrich Beyer
grade
Preferred source (of 3)‎

Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain function

Pharmaceutical Statistics
2015-11 | Journal article
DOI: 10.1002/pst.1706
Part of ISSN: 1539-1604
Source: Self-asserted source
Ulrich Beyer

A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.

Diabetes, obesity & metabolism
2015-08 | Journal article
DOI: 10.1111/dom.12538
PMID: 26179482
Contributors: Ikeda S; Takano Y; Cynshi O; Tanaka R; Christ AD; Boerlin V; Beyer U; Beck A; Ciorciaro C; Meyer M et al.
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

P.2.f.027 The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study

European Neuropsychopharmacology
2014-10 | Journal article
DOI: 10.1016/s0924-977x(14)70748-5
Part of ISSN: 0924-977X
Source: Self-asserted source
Ulrich Beyer

Bayesian adaptive designs in single ascending dose trials in healthy volunteers

British Journal of Clinical Pharmacology
2014-08 | Journal article
DOI: 10.1111/bcp.12344
Part of ISSN: 0306-5251
Source: Self-asserted source
Ulrich Beyer

Issues in the assessment of non-inferiority: perspectives drawn from case studies

Pharmaceutical Statistics
2011-09 | Journal article
DOI: 10.1002/pst.512
Part of ISSN: 1539-1604
Source: Self-asserted source
Ulrich Beyer

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
2011-04 | Journal article
DOI: 10.1093/ndt/gfr160
PMID: 21505096
PMC: PMC3224113
Contributors: Roger SD; Locatelli F; Woitas RP; Laville M; Tobe SW; Provenzano R; Golper TA; Ruangkanchanasetr P; Lee HY; Wu KD et al.
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
2010-06 | Journal article
DOI: 10.1093/ndt/gfq305
PMID: 20522670
PMC: PMC2989790
Contributors: Carrera F; Lok CE; de Francisco A; Locatelli F; Mann JF; Canaud B; Kerr PG; Macdougall IC; Besarab A; Villa G et al.
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease.

Clinical nephrology
2010-02 | Journal article
DOI: 10.5414/cnp73094
PMID: 20129016
Contributors: Locatelli F; Mann JF; Aldigier JC; Sanz Guajardo D; Schmidt R; Van Vlem B; Sulowicz W; Dougherty FC; Beyer U
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.

Hemodialysis international. International Symposium on Home Hemodialysis
2009-11 | Journal article
DOI: 10.1111/j.1542-4758.2009.00421.x
PMID: 19888948
Contributors: Kessler M; Martínez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

Hepcidin as a predictor of response to epoetin therapy in anemic cancer patients.

Clinical chemistry
2009-04 | Journal article
DOI: 10.1373/clinchem.2008.121285
PMID: 19406916
Contributors: Ukarma L; Johannes H; Beyer U; Zaug M; Osterwalder B; Scherhag A
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
2008-06 | Journal article
DOI: 10.1093/ndt/gfn320
PMID: 18586762
PMC: PMC2568005
Contributors: Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C et al.
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

Clinical journal of the American Society of Nephrology : CJASN
2008-02 | Journal article
DOI: 10.2215/CJN.00480107
PMID: 18287255
PMC: PMC2390949
Contributors: Macdougall IC; Walker R; Provenzano R; de Alvaro F; Locay HR; Nader PC; Locatelli F; Dougherty FC; Beyer U; ARCTOS Study Investigators
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.

American journal of kidney diseases : the official journal of the National Kidney Foundation
2007-12 | Journal article
DOI: 10.1053/j.ajkd.2007.08.013
PMID: 18037099
Contributors: Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.

American journal of nephrology
2007-11 | Journal article
DOI: 10.1159/000111115
PMID: 18004064
Contributors: Spinowitz B; Coyne DW; Lok CE; Fraticelli M; Azer M; Dalal S; Villa G; Rosansky S; Adamis H; Beyer U et al.
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

Lancet (London, England)
2007-10 | Journal article
DOI: 10.1016/s0140-6736(07)61599-2
PMID: 17950856
Contributors: Levin NW; Fishbane S; Cañedo FV; Zeig S; Nassar GM; Moran JE; Villa G; Beyer U; Oguey D; MAXIMA study investigators
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.

Current medical research and opinion
2007-05 | Journal article
DOI: 10.1185/030079907x182103
PMID: 17519064
Contributors: Locatelli F; Villa G; de Francisco AL; Albertazzi A; Adrogue HJ; Dougherty FC; Beyer U; BA16286 Study Investigators
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Clinical journal of the American Society of Nephrology : CJASN
2007-05 | Journal article
DOI: 10.2215/cjn.03631006
PMID: 17699476
Contributors: Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U; PROTOS Study Investigators
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.

Clinical therapeutics
2007-04 | Journal article
DOI: 10.1016/j.clinthera.2007.04.014
PMID: 17617286
Contributors: Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U; Ba16285 Study Investigators
Source: Self-asserted source
Ulrich Beyer via Europe PubMed Central

Trendmodellierung durch Zustandsraummodelle bei der Analyse von Längsschnittdaten unter Berücksichtigung von innerindividueller Korrelation

Medizinische Informatik, Biometrie und Epidemiologie, GMDS '96, 41. Jahrestagung der GMDS, Bonn, September 1996
1996 | Conference paper
Source: Self-asserted source
Ulrich Beyer
How many people are using ORCID?